Evidence map›Paper›PMID 41593906›Full record

ArticleAnnals of medicine2026

Clinicopathological characteristics and therapeutic outcomes in patients with non-small cell lung cancer harboring

Yan Liu, Hui Li, Xiang Li, Heran Cui, Rixin Li, Jing Zhu, Hongxia Cui, Ying Liu, Ying Cheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yan LiuMedical Oncology Translational Research Lab, Jilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun, China.ORCID 0000-0001-7374-7445
Hui LiMedical Oncology Translational Research Lab, Jilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun, China.
Xiang LiMedical Oncology Translational Research Lab, Jilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun, China.
Heran CuiBiobank, Jilin Provincial Cancer Hospital, Changchun, China.
Rixin LiBiobank, Jilin Provincial Cancer Hospital, Changchun, China.
Jing ZhuDepartment of Medical Thoracic Oncology, Jilin Cancer Hospital, Changchun, China.
Hongxia CuiDepartment of Medical Thoracic Oncology, Jilin Cancer Hospital, Changchun, China.
Ying LiuDepartment of Medical Thoracic Oncology, Jilin Cancer Hospital, Changchun, China.
Ying ChengMedical Oncology Translational Research Lab, Jilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the clinical characteristics and impact of

methodsA total of 2,821 patients with NSCLC who underwent next-generation sequencing were retrospectively included. The frequency and types of

results

conclusions

Indexed as

Carcinoma, Non-Small-Cell LungDNA HelicasesLung NeoplasmsNuclear ProteinsTranscription FactorsAdultAgedAged, 80 and overErbB ReceptorsFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutationProtein Kinase InhibitorsDNA HelicasesEGFR protein, humanErbB ReceptorsNuclear ProteinsProtein Kinase InhibitorsSMARCA4 protein, humanTranscription FactorsTumor Suppressor Protein p53clinicopathological characteristicsNGSNSCLCSMARCA4therapeutic outcomes

Identifiers

PMID41593906
PMCPMC12854217

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.